Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018

Recker, Matthew J.; Kuo, Cathleen C.; Prasad, Dheerendra; Attwood, Kristopher; Plunkett, Robert J.

doi:10.1007/s11060-022-04085-6

Cited by 10 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…38 Furthermore, recent studies have identified the increasing incidence trend of WHO grade 2 meningiomas, highlighting the importance of our results. 39 Our model-based cost-effectiveness findings were similar to published results on 68 Ga-DOTATATE PET/CT in patients with neuroendocrine tumors. A cost-effectiveness study performed by Froelich et al 40 determined that 68 Ga-DOTATATE PET/CT is cost-effective for detecting neuroendocrine tumors compared with Indium 111-pentetreotide SPECT/CT and CT alone, respectively.…”

Section: Discussionsupporting

confidence: 87%

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

Rodríguez¹,

Martinez²,

Mahase³

et al. 2023

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: While contrast-enhanced MR imaging is the criterion standard in meningioma diagnosis and treatment response assessment, gallium 68 Ga-DOTATATE PET/MR imaging has increasingly demonstrated utility in meningioma diagnosis and management. Integrating 68 Ga-DOTATATE PET/MR imaging in postsurgical radiation planning reduces the planning target volume and organ-at-risk dose. However, 68 Ga-DOTATATE PET/MR imaging is not widely implemented in clinical practice due to higher perceived costs. Our study analyzes the cost-effectiveness of 68 Ga-DOTATATE PET/MR imaging for postresection radiation therapy planning in patients with intermediate-risk meningioma. MATERIALS AND METHODS:We developed a decision-analytical model based on both recommended guidelines on meningioma management and our institutional experience. Markov models were implemented to estimate quality-adjusted life-years (QALY).

show abstract

Section: Discussionsupporting

confidence: 87%

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

Rodríguez¹,

Martinez²,

Mahase³

et al. 2023

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…Meningiomas are the most common type of CNS tumor (>37%) and comprise a histologically and molecularly heterogeneous group of tumors [ 26 , 27 ]. Atypical (WHO grade 2) and anaplastic (WHO grade 3) meningiomas make up 5–7% and 3–5% of all meningiomas, respectively [ 28 ].…”

Section: Rare Central Nervous System Tumorsmentioning

confidence: 99%

The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors

2023

View full text Add to dashboard Cite

Establishing novel therapies for rare central nervous system (CNS) tumors is arduous due to challenges in conducting clinical trials in rare tumors. Immunotherapy treatment has been a rapidly developing field and has demonstrated improvements in outcomes for multiple types of solid malignancies. In rare CNS tumors, the role of immunotherapy is being explored. In this article, we review the preclinical and clinical data of various immunotherapy modalities in select rare CNS tumors, including atypical meningioma, aggressive pituitary adenoma, pituitary carcinoma, ependymoma, embryonal tumor, atypical teratoid/rhabdoid tumor, and meningeal solitary fibrous tumor. Among these tumor types, some studies have shown promise; however, ongoing clinical trials will be critical for defining and optimizing the role of immunotherapy for these patients.

show abstract

“…They usually grow slowly [8], and can reach extensive diameters until the occurrence of symptoms. Although, they are generally considered benign (WHO Grade 1), approximately 7% present as atypical (Grade 2) and 2% as malignant (Grade 3) meningiomas [9, 10]. Grade 1 meningiomas can be treated curative by surgical resection or non‐invasively with stereotactic radiation [11].…”

Section: Origin Of Different Tumor Cell Typesmentioning

confidence: 99%

Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment

Kienzler,

Becher

2023

Eur J Immunol

View full text Add to dashboard Cite

Malignant brain tumors lack effective treatment, that can improve their poor overall survival achieved with standard of care. Advancement in different cancer treatments has shifted the focus in brain tumor research and clinical trials toward immunotherapy‐based approaches. The investigation of the immune cell landscape revealed a dominance of myeloid cells in the tumor microenvironment. Their exact roles and functions are the subject of ongoing research. Current evidence suggests a complex interplay of tumor cells and myeloid cells with competing functions toward support vs. control of tumor growth.Here, we provide a brief overview of the three most abundant brain tumor entities: meningioma, glioma, and brain metastases. We also describe the field of ongoing immunotherapy trials and their results, including immune checkpoint inhibitors, vaccination studies, oncolytic viral therapy, and CAR‐T cells. Finally, we summarize the phenotypes of microglia, monocyte‐derived macrophages, border‐associated macrophages, neutrophils, and potential novel therapy targets.

show abstract

Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018

Cited by 10 publications

References 30 publications

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors

Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment

Contact Info

Product

Resources

About

Incidence trends and survival analysis of atypical meningiomas: a population-based study from 2004 to 2018

Cited by 10 publications

References 30 publications

Cost-Effectiveness Analysis of68Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

Cost-Effectiveness Analysis of68Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors

Immunity in malignant brain tumors: Tumor entities, role of immunotherapy, and specific contribution of myeloid cells to the brain tumor microenvironment

Contact Info

Product

Resources

About

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma

Cost-Effectiveness Analysis of⁶⁸Ga-DOTATATE PET/MRI in Radiotherapy Planning in Patients with Intermediate-Risk Meningioma